Fri, Apr 19, 2024
A A A
Welcome Guest
Free Trial RSS pod
Get FREE trial access to our award winning publications
Industry Updates

Barclay Hedge Fund Index gains 1.63% in December; Healthcare & Biotechnology Index up 13.79% in 2012 (+8.27% 2012)

Monday, January 14, 2013
Opalesque Industry Update: Hedge funds gained 1.63% in December, according to the Barclay Hedge Fund Index compiled by BarclayHedge. The Index had positive returns in 10 out of 12 months in 2012, and was up 8.27% at year-end.

“Buoyant equity markets at the beginning of the month collided with fiscal cliff fears at mid-month, only to explode higher on December 31st,” says Sol Waksman, founder and president of BarclayHedge.

The Barclay Pacific Rim Equities Index was up 3.17% in December, Emerging Markets gained 2.87%, European Equities were up 2.24%, Equity Long Bias gained 2.04%, and Distressed Securities added 1.95%.

“Hedge fund returns outpaced the S&P 500 for a third consecutive month in December, but stilled lagged by 7.76 percent at year-end,” says Waksman.

Three of Barclay’s 18 hedge fund strategies lost ground in December. The Equity Short Bias Index dropped 5.97%, Technology lost 0.33%, and Equity Market Neutral slipped 0.06%.

The Healthcare & Biotechnology Index led all hedge fund strategies in 2012 with a 13.79% gain, Distressed Securities gained 12.05%, the European Equities Index was up 10.17%, Emerging Markets added 9.94%, Equity Long Bias was up 9.34%, and Fixed Income Arbitrage gained 9.33%.

“Now that the boomer generation has begun to swell the ranks of senior citizens and Obamacare is the law of the land, the outlook for healthcare and biotech appears to be bullish,” says Waksman.

The Equity Short Bias Index was the only losing hedge fund strategy in 2012, suffering a negative return of 24.18%. This is the biggest one-year loss for Equity Short Bias since BarclayHedge began tracking its performance in 1997. The previous record was a 23.95% loss in 2003.

The Barclay Fund of Funds Index gained 1.05% in December, and was up 4.60% in 2012.

BarclayHedge

Press Release

BM

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Previous Opalesque Exclusives                                  
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. KKR raises $6.4bn for the largest pan-Asia infrastructure fund[more]

    Laxman Pai, Opalesque Asia: The New York-based global investment firm KKR has raised a record $6.4bn for its second Asia-focused infrastructure fund, underlining investors' continued appetite for private markets. According to a media release from the alternative assets manager, the figure top

  2. Bucking the trend, top hedge fund makes plans for a second SPAC[more]

    From Institutional Investor: SPACs aren't dead. At least not to the folks at Cormorant Asset Management. The life sciences firm, whose hedge fund topped its peers in 2023, is confident it will match the success of its first blank-check company. Last week, the life sciences and biopharma speciali

  3. Benefit Street Partners closes fifth fund on $4.7 billion[more]

    Bailey McCann, Opalesque New York: Benefit Street Partners has closed its fifth flagship direct lending vehicle, BSP Debt Fund V, with $4.7 billion of investable capital across the strategy. Benefit Street invests primarily in privately originated, floating rate, senior secured loans. The fun

  4. 4 hedge fund themes that are working in 2024[more]

    From The Street: A poor earnings report from Tesla (TSLA) has not hurt the indexes on Thursday. The decline in Tesla stock, which is losing its position in the Magnificent Seven pantheon, is more than offset by strong earnings from IBM (IBM) and ServiceNow (NOW) . In addition, the much higher-t

  5. Opalesque Exclusive: A global macro fund eyes opportunities in bonds[more]

    Bailey McCann, Opalesque New York for New Managers: Munich-based ThirdYear Capital rebounded in 2023, following a tough year for global macro. The firm's flagship ART Global Macro strategy finished the year up 1